Results 41 to 50 of about 14,652 (127)

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

Journal of Diabetes Investigation, 2023
Aims/Introduction The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes and established ...
Dae Jung Kim, Wayne H‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino, EMPRISE East Asia Study Group   +15 more
doaj   +1 more source

The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications

Molecules
Type 2 diabetes mellitus is a multifactorial disorder whose primary manifestation usually initiates with elevated blood sugar levels. Several antidiabetic agents are used to manage type 2 diabetes mellitus, of which empagliflozin is an oral sodium ...
Wael Abu Dayyih, Zainab Zakaraya, Mohammad Hailat, Nafe M. Al-Tawarah, Sahem Alkharabsheh, Haya Khalid Nadher, Zeyad Hailat, Samia M. Alarman, Anas Khaleel, Riad Awad   +9 more
doaj   +1 more source

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

BMJ Open Diabetes Research & Care, 2019
Objective We reported previously that empagliflozin—a sodium-glucose cotransporter (SGLT) 2 inhibitor—exhibited preventive effects against obesity. However, it was difficult to extrapolate these results to human subjects. Here, we performed a therapeutic
Tsuguhito Ota, Shuichi Kaneko, Liang Xu, Naoto Nagata, Guanliang Chen, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Yuriko Sakai   +8 more
doaj   +1 more source

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Biochemistry and Biophysics Reports, 2019
Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice ...
Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, Takeshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Ryoko Motonaga, Takashi Fukuda, Makito Tanabe, Toshihiko Yanase   +10 more
doaj   +1 more source

5.1 EFFECTS OF THE SGLT-2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES

Artery Research, 2017
Background: The selective sodium-glucose cotransporter 2 (SGLT-2) inhibitor empagliflozin leads to improved cardiovascular, renal and heart failure outcome in secondary prevention.
Christian Ott, Kristina Striepe, Agnes Jumar, Marina Karg, Markus Schneider, Dennis Kannenkeril, Roland Schmieder   +6 more
doaj   +1 more source

Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia

Frontiers in Pharmacology
Background and aimsRecent studies suggest that empagliflozin reduces total and cardiovascular mortality in both diabetic and nondiabetic subjects. Although the exact mechanism is unclear, it is understood to positively affect myocardial energetics ...
Denisa Miklankova, Denisa Miklankova, Irena Markova, Martina Hüttl, Hana Malinska   +4 more
doaj   +1 more source

Role of Empagliflozin in heart failure with severe aortic stenosis before valve replacement: EASTER-HF study

Indian Heart Journal
We evaluated empagliflozin in severe DAS patients with HF before AVR. HF patients with LVEF 30–80 % and NYHA functional class II-IV symptoms got empagliflozin 10 mg or not within 6 months before AVR, along with SOC. Adding empagliflozin to the SOC before
Pankaj Jariwala, Gururaj Pramod Kulkarni, Arshad Punjani, Harikishan Boorugu, Dilip Gude   +4 more
doaj   +1 more source

Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial

BMC Research Notes
Objective To evaluate the effects of empagliflozin, sitagliptin, and metformin on the glycemic indices and cardiometabolic control of patients with type 2 diabetes mellitus (T2DM). Results The significant changes in FBS from baseline to week 12 were − 23.
Naimeh Mesri Alamdari, Maryam Barghaman, Neda Roshanravan, Majid Mobasseri, Helda Tutunchi, Amir Baharami, Akbar Aliasgarzadeh, Vahideh Sadra   +7 more
doaj   +1 more source

Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Heart failure with preserved ejection fraction (HFpEF) is a multifaceted syndrome with high morbidity and mortality. Empagliflozin, an SGLT2 (sodium–glucose cotransporter 2) inhibitor, reduces adverse events in patients with HFpEF regardless ...
Xinyu Hu, Dan Li, Weijie Chen, Hongyu Kuang, Dan Yang, Zhiyan Gong, Yuxiang Long, Guangliang Liu, Kai Wang, Mengshi Xia, Yanping Xu, Yuehui Yin   +11 more
doaj   +1 more source

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

Diabetes, Metabolic Syndrome and Obesity, 2014
Steven P Vickers,1 Sharon C Cheetham,1 Katie R Headland,1 Keith Dickinson,1 Rolf Grempler,2 Eric Mayoux,2 Michael Mark,2 Thomas Klein2 1RenaSci, BioCity Nottingham, Nottingham, UK; 2Boehringer Ingelheim Pharma, Biberach an der Riss, Germany Abstract ...
Vickers SP, Cheetham SC, Headl, KR, Dickinson K, Grempler R, Mayoux E, Mark M, Klein T   +8 more
doaj